New peptide drugs could take aim at a broader range of proteins that cause certain cancers, viral infections, and brain ...

Advances in neovascular macular degeneration, presented at ASRS 2025, include efficacy of aflibercept 8 mg as well as ...

New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

The brain’s map of the body remains largely unaffected by amputation, potentially informing phantom limb pain management and ...

A phase 3 trial suggests reducing the use of cisplatin when treating nasopharyngeal carcinoma with toripalimab-based ...

In nine studies (76 patients), the anti-IgE monoclonal antibody omalizumab (Xolair), given every 2-4 weeks at doses ranging ...

The American College of Obstetricians and Gynecologists (ACOG) has issued new guidelines on deferred umbilical cord clamping ...

Many doctors adopt damaging lifestyle ‘survival skills’ during residency and keep them for years. Here’s how to spot — and ...

A UK study shows that ADHD in young women increased during the COVID-19 pandemic, peaking in the age group 20-24 years; ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

Recently, second-generation anti-VEGF agents, including brolucizumab, faricimab, and 8 mg aflibercept, have become available ...

In phase 3 APOLLO trial, ATRA-ATO combination therapy showed superior outcomes for high-risk acute promyelocytic leukemia.